NCT01756339View on ClinicalTrials.gov

Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

PHASE3CompletedINTERVENTIONAL

Enrollment

860

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Community-acquired Bacterial Pneumonia

Interventions

DRUG

Solithromycin

DRUG

Moxifloxacin

OTHER

Placebo to match solithromycin

Trial Locations (119)

1035

Witbank

1055

Middelburg

1121

Budapest

1122

Budapest

1125

Budapest

1233

Sofia

1336

Sofia

1426

Buenos Aires

1431

Sofia

Sofia

1500

Benoni

1685

Halfway House

1709

Sofia

1739

Krugersdorp

2300

Pernik

4400

Nyíregyháza

6000

Kecskemét

6014

Korsten

6850

Worcester

7002

Rousse

7530

Cape Town

7570

Cape Town

7764

Cape Town

9300

Bloemfontein

10205

Santo Domingo

10511

Santo Domingo

10617

Tallinn

13619

Tallinn

19335

Downingtown

20090

Lublin

27356

Rotenburg (Wümme)

28046

Madrid

28222

Majadahonda

28850

Madrid

29485

Summerville

30096

Duluth

30173

Hanover

31011

Krakow

32713

DeBary

32720

DeLand

33126

Miami

33144

Miami

33606

Tampa

34769

Saint Cloud

43035

Columbus

46026

Valencia

51014

Tartu

57702

Rapid City

59701

Butte

65719

Hofheim

77011

Houston

77030

Houston

77070

Houston

77093

Houston

77372

Splendora

90015

Los Angeles

90153

Lodz

90502

Torrance

91105

Pasadena

91206

Glendale

91342

Sylmar

91345

Mission Hills

93030

Oxnard

95100

Zgierz

109240

Moscow

111539

Moscow

115446

Moscow

119991

Moscow

123182

Moscow

125206

Moscow

125284

Moscow

192242

Saint Petersburg

193312

Saint Petersburg

194354

Saint Petersburg

Saint Petersburg

195271

Saint Petersburg

196211

Saint Petersburg

196247

Saint Petersburg

197022

Saint Petersburg

198205

Saint Petersburg

199106

Saint Petersburg

200515

Craiova

214019

Smolensk

Smolensk

300310

Timișoara

454008

Chelyabinsk

700115

Iași

02740

New Bedford

B1900AVG

La Plata

B1657BHD

Loma Hermosa

B7000AXD

Tandil

X5000JRD

Córdoba

S2000CVB

Rosario

S3000EOZ

Santa Fe

T4000IAR

San Miguel de Tucumán

C1425BEA

Buenos Aires

C1120AAF

Caba

T6G 2B7

Edmonton

V1Y 1S1

Vancouver

K6H 4M4

Cornwall

H1T 2M4

Montreal

266 01

Beroun

EC090103

Guayaquil

Unknown

Guayaquil

Quito

LV5417

Daugavpils

LV 3414

Liepāja

LV-1002

Riga

LV-1057

Riga

00921

San Juan

010825

Bucharest

021659

Bucharest

030303

Bucharest

0380

Thabazimbi

0083

Hillcrest

0001

Pretoria

08916

Badalona

08036

Barcelona

08304

Mataró

Sponsors

Lead Sponsor

Melinta Therapeutics, Inc.

All Listed Sponsors

lead

Melinta Therapeutics, Inc.

INDUSTRY

NCT01756339 - Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia | Biotech Hunter | Biotech Hunter